Results 301 to 310 of about 118,448 (336)
Some of the next articles are maybe not open access.
Medical Clinics of North America, 1999
Dopamine agonists have been used in the treatment of Parkinson's disease (PD) since the mid 1970s. With the approval of two new agents in 1997, the number available in the United States is up to four; bromocriptine, pergolide, pramipexole, ropinirole.
openaire +2 more sources
Dopamine agonists have been used in the treatment of Parkinson's disease (PD) since the mid 1970s. With the approval of two new agents in 1997, the number available in the United States is up to four; bromocriptine, pergolide, pramipexole, ropinirole.
openaire +2 more sources
Dopamine agonists in Parkinson’s disease
Expert Opinion on Investigational Drugs, 2003Levodopa (LD), the immediate precursor of dopamine, is the most effective agent in the treatment of Parkinson's disease (PD). While quite successful in treating the primary motor deficits of PD, most patients eventually develop LD-related motor fluctuation, dyskinesias and other adverse effects associated with chronic LD therapy.
Ron Tintner, Joseph Jankovic
openaire +3 more sources
Dopamine Agonists in the Treatment of Schizophrenia
1986Publisher Summary Behavioral, neurochemical, ligand binding, and single cell unit recording studies suggest the existence of two distinct classes of dopamine (DA) receptors: autoreceptors, which are present on the membranes of dopamine neurons, and postsynaptic receptors located on the neurons with which dopamine neurons synapse.
DEL ZOMPO, MARIA +3 more
openaire +5 more sources
Dopamine agonists for cocaine dependence
2003Cocaine is a major drug of abuse. Cocaine dependence is a common and serious condition, which has become nowadays a substantial public health problem. There is a wide and well documented range of consequences associated to chronic use of this drug, such as medical, psychological and social problems, including the spread of infectious diseases (e.g ...
Lima Reisser Aa +3 more
openaire +5 more sources
Neuroprotection and dopamine agonists
Neurology, 2002Several factors are known to be capable of inducing relatively selective dopaminergic cell death in the substantia nigra and inducing the clinical features that characterize Parkinson's disease (PD). Neuronal toxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can induce parkinsonism in human and animal models, and rotenone, another ...
openaire +3 more sources
Dopamine agonists in Parkinson's disease
Neurology, 1995The main pathologic hallmark of Parkinson's disease is a degeneration of the dopaminergic cells in the substantia nigra, pars compacta and--to a lesser extent--in the ventral tegmental area. Striatal dopamine concentrations are significantly reduced before clinical symptoms become apparent.
Gerrit Tissingh +3 more
openaire +3 more sources
Neurology, 2002
Although all dopaminergic drugs are effective in reducing tremor, no single drug has been shown to be clearly superior in the treatment of tremor. Levodopa produces a mean improvement of 30 to 50% in the Unified Parkinson's Disease Rating Scale (UPDRS) subtest for rest tremor. Comparable improvement is achieved with the dopamine agonists.
openaire +3 more sources
Although all dopaminergic drugs are effective in reducing tremor, no single drug has been shown to be clearly superior in the treatment of tremor. Levodopa produces a mean improvement of 30 to 50% in the Unified Parkinson's Disease Rating Scale (UPDRS) subtest for rest tremor. Comparable improvement is achieved with the dopamine agonists.
openaire +3 more sources
Dopamine agonists and Parkinson's disease
Clinical Neurology and Neurosurgery, 1984The therapeutic use of dopamine agonists for Parkinson's disease, clinical guidelines for their introduction into antiparkinson regimens, and their range of adverse effects are reviewed. The role played by the dopaminomimetic ergots in elucidating dopamine receptor function, and laboratory methods that identify dopamine agonists, are also examined.
D.B. Calne, K. Burton
openaire +3 more sources
Expert Opinion on Pharmacotherapy, 2002
(2002). Synthetic dopamine agonists. Expert Opinion on Pharmacotherapy: Vol. 3, No. 4, pp. 363-364.
openaire +3 more sources
(2002). Synthetic dopamine agonists. Expert Opinion on Pharmacotherapy: Vol. 3, No. 4, pp. 363-364.
openaire +3 more sources
Dopamine agonists in schizophrenia: a review
European Neuropsychopharmacology, 1995Although it is unlikely that the different types of course and severity of schizophrenia are caused by one neurochemical abnormality alone, indirect pharmacological evidence still suggests a relative excess of dopaminergic activity being implicated in the pathogenesis of most of the schizophrenic symptoms, e.g. positive symptomatology.
Otto Benkert +2 more
openaire +2 more sources